Previous 10 | Next 10 |
2023-08-14 13:30:00 ET Summary After making a new 2023 high on July 31, the market is now in the process of consolidating its gains and expanding its participation. The Death Cross ended on February 2, 2023. We are now in a Golden Cross configuration, with the 50-day above the 200...
2023-08-11 08:16:36 ET Cano Health ( CANO ) -48% after Q2 earning release . Yield10 Bioscience ( YTEN ) -46% . Maxeon Solar Technologies, Ltd. ( MAXN ) -26% after Q2 earning release . LQR House ( LQR ) -17% . Vistagen Therapeutics ( ...
2023-08-09 08:32:37 ET Tigo Energy ( TYGO ) -37% reports record revenues and gross profit for second quarter 2023. Bruush Oral Care ( BRSH ) -29% . Fitell Corporation ( FTEL ) -26% . Veritone ( VERI ) -26% after Q2 earning release . ...
2023-08-08 22:58:10 ET Nektar Therapeutics (NKTR) Q2 2023 Earnings Conference Call August 8, 2023, 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and CEO Dr. Jonathan Zalevsky - Chief, Resea...
2023-08-08 17:00:29 ET Nektar Therapeutics press release ( NASDAQ: NKTR ): Q2 GAAP EPS of -$0.27 beats by $0.01 . Revenue of $20.5M (-5.1% Y/Y) misses by $1.33M . Cash and investments in marketable securities at June 30, 2023, were $409.4 million as compared to...
Nektar Therapeutics Reports Second Quarter 2023 Financial Results PR Newswire SAN FRANCISCO , Aug. 8, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023 . Cash an...
2023-08-08 13:05:05 ET Summary Eli Lilly and Company's Q2 2023 earnings were boosted by strong sales growth of three key products in its pipeline: Verzenio, Jardiance, and Mounjaro. Verzenio, a breast cancer drug, saw significant sales growth due to its approval for multiple indic...
2023-08-08 12:10:35 ET Summary Nektar Therapeutics' lead compound rezpegaldesleukin shows more promising results after errors in efficacy calculations were discovered. Nektar shares surged over 90% following the news, with plans to initiate a Phase IIb study in atopic dermatitis. ...
2023-08-08 06:27:00 ET Is Short or Long Term Investing in Penny Stocks Better? Penny stocks represent a unique opportunity for both seasoned and novice investors to diversify their portfolio and potentially reap significant returns. Characterized by their low stock price, often under $5...
2023-08-07 17:35:20 ET Nektar Therapeutics ( NASDAQ: NKTR ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.22 and the consensus Revenue Estimate is $21.83M (+1.1% Y/Y). For further details se...
News, Short Squeeze, Breakout and More Instantly...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results fo...
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire SAN FRANCISCO ,...